Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Open Label Dose Escalation and Double-Blind, Placebo-Controlled Evaluation of M40403, for the Prevention of the Dose Limiting Toxicities of High Dose IV Bolus IL-2 Treatment of Metastatic Melanoma or Renal Cell Carcinoma.

NCT00033956 is registered in ClinicalTrials.gov with MetaPhore Pharmaceuticals as lead sponsor.

NCT NCT00033956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00033956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Open Label Dose Escalation and Double-Blind, Placebo-Controlled Evaluation of M40403, for the Prevention of the Dose Limiting Toxicities of High Dose IV Bolus IL-2 Treatment of Metastatic Melanoma or Renal Cell Carcinoma.
Lead sponsor
MetaPhore Pharmaceuticals
Phase
Phase 1/2
Overall status
Suspended
Start date
December 31, 2001
Completion date
Not reported
Enrollment
48
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

il-2 induced hypotension